Last reviewed · How we verify
GLS-012
At a glance
| Generic name | GLS-012 |
|---|---|
| Sponsor | Guangzhou Gloria Biosciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLS-012 CI brief — competitive landscape report
- GLS-012 updates RSS · CI watch RSS
- Guangzhou Gloria Biosciences Co., Ltd. portfolio CI